PDF(Pubmed)
Abstract：
Solid organ transplant (SOT) recipients are particularly susceptible to infections caused by multidrug-resistant organisms (MDRO) and are often the first to be affected by an emerging resistant pathogen. Unfortunately, their prevalence and impact on morbidity and mortality according to the type of graft is not systematically reported from high-as well as from low and middle-income countries (HIC and LMIC). Thus, epidemiology on MDRO in SOT recipients could be subjected to reporting bias. In addition, screening practices and diagnostic resources may vary between countries, as well as the availability of new drugs. In this review, we aimed to depict the burden of main Gram-negative MDRO in SOT patients across HIC and LMIC and to provide an overview of current diagnostic and therapeutic resources.
摘要：
实体器官移植（SOT）受者特别容易受到多药耐药生物（MDRO）引起的感染，并且通常是第一个受到新出现的耐药病原体的影响。不幸的是,高收入国家以及低收入和中等收入国家(HIC和LMIC)没有系统地报告它们的患病率以及根据移植物类型对发病率和死亡率的影响.因此，SOT接受者的MDRO流行病学可能会受到报告偏见的影响。此外,筛查实践和诊断资源可能因国家而异，以及新药的可用性。在这次审查中,我们旨在描述HIC和LMIC中SOT患者的主要革兰氏阴性MDRO负担,并概述当前的诊断和治疗资源.
